Novel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein Aggregates
exRNA 载体的新型分离方法:细胞外囊泡、脂蛋白颗粒和蛋白质聚集体
基本信息
- 批准号:10483185
- 负责人:
- 金额:$ 54.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgeAnalytical ChemistryAntibodiesAttentionBindingBiochemicalBiologicalBiological FactorsBiologyCatalogsCellsCentrifugationCharacteristicsChargeData SetDetectionDevelopmentDietDiseaseEngineeringEnsureField Flow FractionationGoldHealthHigh Density LipoproteinsHigher Order Chromatin StructureImmobilizationIntervention StudiesLibrariesLipid BilayersLipoproteinsLiquid substanceLocationLow-Density LipoproteinsMLLT2 geneMeasuresMethodologyMethodsMicroRNAsModificationMolecularMorphologic artifactsPhaseProcessProteomicsRNAResolutionRibonucleasesRibonucleoproteinsSamplingSpeedSurfaceTechniquesTechnologyTestingTherapeuticTimeTissuesValidationbasebiological sexdensitydesignextracellularextracellular vesiclesimprovedinhibitorlipidomicsliquid biopsymembermolecular carriernovelparticlepreservationprotein aggregationsample collectionscreeningsensorsexvalidation studies
项目摘要
ABSTRACT
Extracellular RNA (exRNA) is a particularly attractive molecular component of liquid biopsy because RNA
species can be specifically amplified. Of the three major classes of exRNA vehicle—extracellular vesicles
(EVs), lipoprotein particles (LPPs), and free ribonucleoproteins (RNPs)—EVs have so far received the most
attention. Within each class, there is also tremendous diversity by physical characteristics of size, density, and
surface charge. Indeed, to our knowledge, no study to date has profiled exRNA in multiple members of the
three carrier classes that have been isolated rigorously from the same samples. There is a strong need to
develop new strategies and controls to ensure that comparisons of exRNA carriers are not confounded by co-
isolation (different classes of carriers present in the same fraction) or contamination (detection of uncomplexed
and/or foreign RNAs introduced during sample collection and processing). To this end, we assemble a team of
experts on EVs, LPPs, and RNPs, along with experts in cutting-edge separation and characterization methods.
In an initial UG3 phase, we will first (Aim 1) use a combination of state-of-the-field physical and biochemical
separation methods to separate a library of eight subtypes of EVs, LPPs, and RNPs from the same biological
samples and with the best achievable purity. “Gold standard” proteomic, lipidomic, glycomic, and RNomic
datasets will be generated. Carefully designed “process” controls will for the first time establish an across-the-
board baseline of contaminants and other artifacts that may complicate interpretation. In Aim 2, we will test
asymmetric field-flow fractionation (AF4) and affinity capture platforms including the ExoView platform and
sensitive electrochemical sensors as superior alternatives to the most commonly used legacy method,
differential centrifugation. We will seek gains in speed, resolution, and purity compared with legacy techniques.
If go/no-go criteria are met by the end of the second year (UG3), we will proceed to a UH3 phase. This phase
will include an Aim 3, validating results in multiple locations and with approximately 6 times the original sample
numbers to account for influence of sex and age. The AF4 method will be further developed with additional
modifications based on our engineering and analytical chemistry expertise, while ExoView technology will be
harnessed to screen antibodies and other affinity materials for rapid isolations and to detect abundant RNA
species directly in immobilized exRNA carriers. Finally, an Aim 4 will assess the biological factor of diet with
valuable samples from intervention studies, along with the possible desirability of collecting samples in RNase
inhibitors to preserve more fragile RNA species. Overall, we hypothesize that 1) AF4, on its own or with
methodologic modifications, as well as 2) novel affinity separation approaches will improve substantially on
ultracentrifuge-based methods in ease and purity and on current state-of-the-art but tedious and lengthy
exRNA carrier separation methods.
抽象的
细胞外RNA(EXRNA)是液体的特别有吸引力的分子成分,因为RNA
物种可以特别放大。
(EVS),脂蛋白颗粒(LPP)和游离核糖核蛋白(RNP) - Eve到目前为止收到的最多
注意每个班级,这也是大小,密度的物理特征的巨大多样性
据我们所知,表面充电。
与同一样品严格隔离的三个载体类别。
制定新的策略和控制,以确保Exrna载体的比较不会被共同混淆
隔离(相同分数中存在的不同类别的载体)或污染
和/或在样本收集和处理过程中引入的外国RNA。
电动汽车,LPP和RNP的专家,以及前沿分离和表征方法的专家。
在最初的UG3阶段,我们将首先(AIM 1)使用现场物理和生化的组合
分离方法将八个亚型的电动汽车,LPP和RNP的库与同一生物学分开。
“黄金标准”蛋白质组学,脂质组,糖和rNomic,rnomic,rnomic,rnomic和rnomic和rnomic,rnomic
数据集将被生成精心设计的“过程”控件
污染物的基线和其他可以在AIM 2中进行的工件。
不对称的场流分馏(AF4)和亲和力捕获平台,包括Exoview平台和
敏感的电化学传感器是最常用的遗产方法的优越选择,
与传统技术相比,我们将寻求速度,分辨率和纯度的提高。
如果在第二年结束时满足GO/No-Go标准(UG3)
将包括一个目标3,验证多个位置的结果,大约是原始样本的6倍
为了进一步开发的性别和年龄的影响。
基于我们的工程分析化学专业知识的修改,而Exoview技术将是
利用筛选抗体和其他材料进行快速隔离并检测丰富的RNA
直接在固定的埃克纳携带者中,目标4将评估饮食的生物学因素
干预研究中的宝贵样本,以及在RNase中收集样品的可能性
抑制剂保留更脆弱的RNA物种,我们假设1)AF4或
方法论修改以及2)新型亲和力分离方法将在很大程度上改善
基于纯度和纯度的超级离心方法以及当前最先进的乏味和冗长的方法
EXRNA载体分离方法。
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Circulating SNORD57 rather than piR-54265 is a promising biomarker for colorectal cancer: common pitfalls in the study of somatic piRNAs in cancer.
- DOI:10.1261/rna.078444.120
- 发表时间:2021-04
- 期刊:
- 影响因子:0
- 作者:Tosar JP;García-Silva MR;Cayota A
- 通讯作者:Cayota A
Letter by Halushka and Witwer Regarding Article, "Circulating MicroRNA-122-5p Is Associated With a Lack of Improvement in Left Ventricular Function After Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellula
Halushka 和 Witwer 关于文章“循环 MicroRNA-122-5p 与经导管主动脉瓣置换术后左心室功能缺乏改善有关,并通过细胞外调节心肌细胞的活力”的信函
- DOI:10.1161/circulationaha.122.061834
- 发表时间:2023
- 期刊:
- 影响因子:37.8
- 作者:Halushka,MarcK;Witwer,KennethW
- 通讯作者:Witwer,KennethW
RI-SEC-seq: Comprehensive Profiling of Nonvesicular Extracellular RNAs with Different Stabilities.
RI-SEC-seq:具有不同稳定性的非囊泡细胞外 RNA 的综合分析。
- DOI:10.21769/bioprotoc.3918
- 发表时间:2021
- 期刊:
- 影响因子:0.8
- 作者:Tosar,JuanPablo;Gámbaro,Fabiana;Castellano,Mauricio;Cayota,Alfonso
- 通讯作者:Cayota,Alfonso
Lipid-Based Nutrient Supplementation Increases High-Density Lipoprotein (HDL) Cholesterol Efflux Capacity and Is Associated with Changes in the HDL Glycoproteome in Children.
- DOI:10.1021/acsomega.1c04811
- 发表时间:2021-11-30
- 期刊:
- 影响因子:4.1
- 作者:Hong BV;Zhu C;Wong M;Sacchi R;Rhodes CH;Kang JW;Arnold CD;Adu-Afarwuah S;Lartey A;Oaks BM;Lebrilla CB;Dewey KG;Zivkovic AM
- 通讯作者:Zivkovic AM
Urinary extracellular vesicles contain mature transcriptome enriched in circular and long noncoding RNAs with functional significance in prostate cancer.
- DOI:10.1002/jev2.12210
- 发表时间:2022-05
- 期刊:
- 影响因子:16
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kenneth W Witwer其他文献
Kenneth W Witwer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kenneth W Witwer', 18)}}的其他基金
Novel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein Aggregates
exRNA 载体的新型分离方法:细胞外囊泡、脂蛋白颗粒和蛋白质聚集体
- 批准号:
9975112 - 财政年份:2019
- 资助金额:
$ 54.9万 - 项目类别:
Novel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein Aggregates
exRNA 载体的新型分离方法:细胞外囊泡、脂蛋白颗粒和蛋白质聚集体
- 批准号:
10470432 - 财政年份:2019
- 资助金额:
$ 54.9万 - 项目类别:
Novel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein Aggregates
exRNA 载体的新型分离方法:细胞外囊泡、脂蛋白颗粒和蛋白质聚集体
- 批准号:
9812105 - 财政年份:2019
- 资助金额:
$ 54.9万 - 项目类别:
Extracellular Vesicle and Extracellular RNA Biomarkers of HIV-1 Central Nervous System Pathogenesis and Cigarette Use
HIV-1 中枢神经系统发病机制和香烟使用的细胞外囊泡和细胞外 RNA 生物标志物
- 批准号:
10217079 - 财政年份:2018
- 资助金额:
$ 54.9万 - 项目类别:
Extracellular Vesicle and Extracellular RNA Biomarkers of HIV-1 Central Nervous System Pathogenesis and Cigarette Use
HIV-1 中枢神经系统发病机制和香烟使用的细胞外囊泡和细胞外 RNA 生物标志物
- 批准号:
9978799 - 财政年份:2018
- 资助金额:
$ 54.9万 - 项目类别:
Extracellular Vesicle and Extracellular RNA Biomarkers of HIV-1 Central Nervous System Pathogenesis and Cigarette Use
HIV-1 中枢神经系统发病机制和香烟使用的细胞外囊泡和细胞外 RNA 生物标志物
- 批准号:
10456790 - 财政年份:2018
- 资助金额:
$ 54.9万 - 项目类别:
Extracellular Vesicle and Extracellular RNA Biomarkers of HIV-1 Central Nervous System Pathogenesis and Cigarette Use
HIV-1 中枢神经系统发病机制和香烟使用的细胞外囊泡和细胞外 RNA 生物标志物
- 批准号:
9788410 - 财政年份:2018
- 资助金额:
$ 54.9万 - 项目类别:
Extracellular Vesicle-Mediated Immunomodulation in HIV Infection and Nicotine Abuse
HIV 感染和尼古丁滥用中细胞外囊泡介导的免疫调节
- 批准号:
9086347 - 财政年份:2015
- 资助金额:
$ 54.9万 - 项目类别:
International Society for Extracellular Vesicles - Education Day & Meeting
国际细胞外囊泡学会 - 教育日
- 批准号:
8910966 - 财政年份:2015
- 资助金额:
$ 54.9万 - 项目类别:
Circulating Cellular and Extracellular Noncoding RNAs in HIV-1 Elite Suppression
HIV-1 Elite 抑制中的循环细胞和细胞外非编码 RNA
- 批准号:
8541944 - 财政年份:2013
- 资助金额:
$ 54.9万 - 项目类别:
相似国自然基金
HTRA1介导CTRP5调控脂代谢通路在年龄相关性黄斑变性中的致病机制研究
- 批准号:82301231
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PLAAT3降低介导线粒体降解异常在年龄相关性白内障发病中的作用及机制
- 批准号:82301190
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
跨尺度年龄自适应儿童头部模型构建与弥漫性轴索损伤行为及表征研究
- 批准号:52375281
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
ALKBH5通过SHP-1调控视网膜色素上皮细胞铁死亡在年龄相关性黄斑变性中的作用机制研究
- 批准号:82301213
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
叶黄素调控脂代谢紊乱所致年龄相关性黄斑病变的血-视网膜屏障损伤机制研究
- 批准号:82373570
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Single molecules with multi-mechanistic modes of action as probative anti-Alzheimer’s agents
具有多机制作用模式的单分子作为有效的抗阿尔茨海默病药物
- 批准号:
10172742 - 财政年份:2021
- 资助金额:
$ 54.9万 - 项目类别:
Single molecules with multi-mechanistic modes of action as probative anti-Alzheimer’s agents
具有多机制作用模式的单分子作为有效的抗阿尔茨海默病药物
- 批准号:
10430206 - 财政年份:2021
- 资助金额:
$ 54.9万 - 项目类别:
Single molecules with multi-mechanistic modes of action as probative anti-Alzheimer’s agents
具有多机制作用模式的单分子作为有效的抗阿尔茨海默病药物
- 批准号:
10640255 - 财政年份:2021
- 资助金额:
$ 54.9万 - 项目类别:
Novel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein Aggregates
exRNA 载体的新型分离方法:细胞外囊泡、脂蛋白颗粒和蛋白质聚集体
- 批准号:
9975112 - 财政年份:2019
- 资助金额:
$ 54.9万 - 项目类别:
Novel Separation Methods for exRNA Carriers: Extracellular Vesicles, Lipoprotein Particles, and Protein Aggregates
exRNA 载体的新型分离方法:细胞外囊泡、脂蛋白颗粒和蛋白质聚集体
- 批准号:
9812105 - 财政年份:2019
- 资助金额:
$ 54.9万 - 项目类别: